Tag: Drug Development
-
IU Bloomington Lab Uncovers Key to Combating Antibiotic Resistance
Breaking the Global Threat: A New Insight from IU Bloomington Antimicrobial resistance—where bacteria and fungi develop defenses against drugs designed to kill them—poses a mounting risk to global public health. The Centers for Disease Control and Prevention (CDC) has repeatedly warned that resistant infections could undermine modern medicine, making routine surgeries and cancer treatments far…
-
IU Bloomington Lab Discovers Key to Antibiotic Resistance
Groundbreaking Finding from the Gerdt Lab at Indiana University Antimicrobial resistance remains one of the most pressing public health challenges of our time. Bacteria and fungi that outsmart antibiotics threaten the effectiveness of treatments for common infections and complicate routine medical procedures. A recent advance from Indiana University Bloomington’s Gerdt Laboratory marks a notable turn…
-
Ascletis Reports Positive Topline Results for Denifanstat (ASC40) in Phase III Open-Label Trial
Summary of Positive topline results for denifanstat (ASC40) Ascletis announced favorable topline results from its Phase III open-label study evaluating denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor. The company highlighted favorable safety and tolerability, with efficacy signals aligning with prior data and reinforcing the potential of ASC40 as a transformative therapeutic option.…
-
Trojan Horse Copper Therapy Targets MRSA: A New Front in Combating Drug-Resistant Bacteria
What is the Trojan Horse copper strategy? Scientists at the University of Arizona College of Medicine – Tucson are pursuing a novel approach that uses copper in a “Trojan horse” delivery system. The idea is to pair copper with a drug or carrier that can sneak past bacterial defenses and release copper inside the cell,…
-
Copper-Powered Trojan Horse Targets MRSA Infections: A New Antibacterial Strategy
New Strategy: Copper-Enhanced Drugs Meet Trojan-Horse Tactics A team at the University of Arizona College of Medicine – Tucson is pursuing a novel form of antibacterial treatment that works in concert with copper to outsmart drug-resistant bacteria. The approach uses a drug that behaves like a Trojan horse, slipping past bacterial defenses and delivering copper…
-
Customizable Protein Platforms: A New Horizon for Cancer Therapy and Beyond
Introduction: A breakthrough in targeted cancer therapy Researchers at the University of Massachusetts Amherst are advancing customizable protein platforms designed to precisely shred or repair cancer-causing proteins within malignant cells. This innovative approach aims to offer targeted therapies that minimize collateral damage to healthy cells, addressing a longstanding challenge in oncology. While the immediate focus…
-
Abcam Joins Innovative Health Initiative’s LIGAND-AI Project to Accelerate AI-Driven Drug Discovery
A Strategic Collaboration to Accelerate AI-Driven Drug Discovery Abcam has joined the Innovative Health Initiative’s (IHI) LIGAND-AI project, a collaborative effort designed to speed up AI-powered drug discovery through an open-science framework. The public-private partnership is led by the Structural Genomics Consortium (SGC) in collaboration with Pfizer, and it brings together industry, academia, and non-profit…
-
Autobahn Therapeutics Unveils Preclinical Data Supporting Restorative Neuroplasticity Mechanism of Elunetirom
New Preclinical Findings Spotlight a Restorative Neuroplasticity Mechanism Autobahn Therapeutics has presented new preclinical data for its investigational drug, Elunetirom, at the American College of Neuropsychopharmacology (ACNP) Annual Meeting. The research centers on a novel restorative neuroplasticity mechanism believed to promote recovery and resilience in neuropsychiatric and neuroimmunologic disorders. The findings add to the company’s…
-
Antengene at JPM: Strong Clinical Data Update and Strategic Focus
Overview Antengene Corporation Limited, a global biotech company focused on discovering, developing and commercializing innovative oncology medicines, delivered a compelling update at the JPMorgan Healthcare Conference. The presentation highlighted a steady cadence of clinical data readouts, coupled with a clear strategic plan to advance its most promising programs and broaden partnerships. Executives emphasized robust early…
-
Quantum tools set to transform life science, researchers say
Quantum tools poised to redefine life science Researchers from Japan’s National Institutes for Quantum Science and Technology (QST) have published a field-defining Perspective that centers the societal payoff of quantum technologies. The authors argue that quantum tools can accelerate multiple stages of life science—from early disease detection to expedited drug development—while also enabling new diagnostic…